SGLT2 inhibitors are particularly effective in reducing heart failure-related outcomes and slowing renal disease progression, while GLP-1 RAs excel in reducing atherosclerotic cardiovascular events, such as myocardial infarction and stroke. This evidence concerns the gene SLC5A2 and Stroke.